LianBio Sponsored ADR (LIAN)
US Market

LianBio Sponsored ADR (LIAN) Stock Price & Analysis


LIAN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.07 - $6.24
Previous Close$2.43
Average Volume (3M)205.84K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)-2.3
Next EarningsMar 29, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-1.05
Shares Outstanding108,353,831
Standard Deviation0.21
10 Day Avg. Volume498,083
30 Day Avg. Volume205,839
Price to Book (P/B)0.99
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside480.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1


What was LianBio Sponsored ADR’s price range in the past 12 months?
LianBio Sponsored ADR lowest stock price was $1.07 and its highest was $6.24 in the past 12 months.
    What is LianBio Sponsored ADR’s market cap?
    Currently, no data Available
    When is LianBio Sponsored ADR’s upcoming earnings report date?
    LianBio Sponsored ADR’s upcoming earnings report date is Mar 29, 2023 which is in 55 days.
      How were LianBio Sponsored ADR’s earnings last quarter?
      LianBio Sponsored ADR released its earnings results on Nov 10, 2022. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.392 by $0.192.
        Is LianBio Sponsored ADR overvalued?
        According to Wall Street analysts LianBio Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does LianBio Sponsored ADR pay dividends?
          LianBio Sponsored ADR does not currently pay dividends.
          What is LianBio Sponsored ADR’s EPS estimate?
          LianBio Sponsored ADR’s EPS estimate is -$0.27.
            How many shares outstanding does LianBio Sponsored ADR have?
            LianBio Sponsored ADR has 108,353,830 shares outstanding.
              What happened to LianBio Sponsored ADR’s price movement after its last earnings report?
              LianBio Sponsored ADR reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.392. Following the earnings report the stock price went up 8.824%.
                Which hedge fund is a major shareholder of LianBio Sponsored ADR?
                Among the largest hedge funds holding LianBio Sponsored ADR’s share is Perceptive Advisors LLC. It holds LianBio Sponsored ADR’s shares valued at 115M.


                  LianBio Sponsored ADR Stock Smart Score

                  The LianBio Sponsored ADR stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  LianBio Sponsored ADR

                  LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Y-Mabs Therapeutics
                  Summit Therapeutics
                  Greenwich LifeSciences

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis